NFKB1 and diffuse large B-cell lymphoma: Oncogenic CARMA1 mutations driving constitutive signaling activity of the CBM complex have initially been discovered in approximately 10% of patients suffering from the aggressive ABC subtype of DLBCL which relies on constitutive NF-κB signaling for survival and proliferation [137].